Lv33
370 积分 2023-08-01 加入
Case report: durable complete response to pembrolizumab plus lenvatinib in a metastatic upper tract urothelial carcinoma patient with high tumor mutational burden and an immune-active tumor microenvironment
1天前
待确认
Homologous recombination repair gene mutations in colorectal cancer favors treatment of immune checkpoint inhibitors
1天前
已完结
Immune Checkpoint Inhibitor Rechallenge After Immune-Related Adverse Events in Patients With Cancer
3天前
已完结
Rapid Advances in Resectable Non–Small Cell Lung Cancer
28天前
已完结
Analysis of rare fusions in NSCLC: Genomic architecture and clinical implications
1个月前
已完结
Impact of bone metastasis on the prognosis of non-small cell lung cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis
3个月前
已完结
Pathologic responses in oligometastatic NSCLC patients treated with neoadjuvant immune checkpoint blockade with and without chemotherapy followed by surgery
4个月前
已完结
Radical Minimally Invasive Surgery After Immuno-chemotherapy in Initially-unresectable Stage IIIB Non-small cell Lung Cancer
4个月前
已完结
Comparison of treatment effect from randomised controlled phase II trials and subsequent phase III trials using identical regimens in the same treatment setting
5个月前
已完结
皖公网安备34019202002308
